RT Journal Article
T1 Non-Alcoholic Fatty Liver Disease in Lean and Non-Obese Individuals: Current and Future Challenges.
A1 Kuchay, Mohammad Shafi
A1 Martínez-Montoro, José Ignacio
A1 Choudhary, Narendra Singh
A1 Fernández-García, José Carlos
A1 Ramos-Molina, Bruno
K1 gut microbiota
K1 insulin resistance
K1 lean NAFLD
K1 metabolic syndrome
K1 visceral adiposity
AB Non-alcoholic fatty liver disease (NAFLD), which approximately affects a quarter of the world's population, has become a major public health concern. Although usually associated with excess body weight, it may also affect normal-weight individuals, a condition termed as lean/non-obese NAFLD. The prevalence of lean/non-obese NAFLD is around 20% within the NAFLD population, and 5% within the general population. Recent data suggest that individuals with lean NAFLD, despite the absence of obesity, exhibit similar cardiovascular- and cancer-related mortality compared to obese NAFLD individuals and increased all-cause mortality risk. Lean and obese NAFLD individuals share several metabolic abnormalities, but present dissimilarities in genetic predisposition, body composition, gut microbiota, and susceptibility to environmental factors. Current treatment of lean NAFLD is aimed at improving overall fitness and decreasing visceral adiposity, with weight loss strategies being the cornerstone of treatment. Moreover, several drugs including PPAR agonists, SGLT2 inhibitors, or GLP-1 receptor agonists could also be useful in the management of lean NAFLD. Although there has been an increase in research regarding lean NAFLD, there are still more questions than answers. There are several potential drugs for NAFLD therapy, but clinical trials are needed to evaluate their efficacy in lean individuals.
SN 2227-9059
YR 2021
FD 2021-09-28
LK https://hdl.handle.net/10668/27018
UL https://hdl.handle.net/10668/27018
LA en
DS RISalud
RD Apr 5, 2025